ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 183 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 4.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4 | -60.0% | 188 | -24.8% | 0.00% | – |
| Q1 2023 | $10 | -9.1% | 250 | 0.0% | 0.00% | – |
| Q4 2022 | $11 | -100.0% | 250 | -89.7% | 0.00% | – |
| Q4 2021 | $181,000 | +5933.3% | 2,428 | +3368.6% | 0.00% | – |
| Q2 2020 | $3,000 | -86.4% | 70 | -84.1% | 0.00% | – |
| Q1 2020 | $22,000 | -58.5% | 441 | -50.6% | 0.00% | – |
| Q3 2019 | $53,000 | +140.9% | 893 | +182.6% | 0.00% | – |
| Q4 2018 | $22,000 | -95.7% | 316 | -92.8% | 0.00% | -100.0% |
| Q2 2018 | $508,000 | +53.5% | 4,390 | -22.2% | 0.00% | -85.7% |
| Q4 2017 | $331,000 | +86.0% | 5,644 | +14.0% | 0.01% | +75.0% |
| Q2 2017 | $178,000 | +3460.0% | 4,953 | +2779.7% | 0.01% | – |
| Q1 2016 | $5,000 | -98.4% | 172 | -98.2% | 0.00% | -100.0% |
| Q4 2015 | $312,000 | +1542.1% | 9,472 | +1622.2% | 0.02% | +2300.0% |
| Q3 2015 | $19,000 | -26.9% | 550 | -4.8% | 0.00% | -50.0% |
| Q2 2015 | $26,000 | -7.1% | 578 | -38.7% | 0.00% | -33.3% |
| Q1 2015 | $28,000 | -67.1% | 943 | -43.8% | 0.00% | -70.0% |
| Q4 2014 | $85,000 | – | 1,679 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |